Physician profile
Gilbert Desmangles
NPI 1285738278
$9,360.86
in general payments reported to CMS, 2019-2025
34 companies · $1,227 in 2025
The $1,227 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,275 · 2020: $915 · 2021: $1,380 · 2022: $1,414 · 2023: $1,875 · 2024: $1,275 · 2025: $1,227.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,377.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,376.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,468.41 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,223.78 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Abbvie INC. | $1,107.19 | 2021-2025 | Ubrelvy, Vraylar, Qulipta |
| Glaxosmithkline, LLC. | $972.48 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Lilly USA, LLC | $619.02 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Amgen INC. | $600.10 | 2019-2025 | Repatha, Otezla, Otezla |
| Pfizer INC. | $425.69 | 2019-2025 | |
| Allergan, INC. | $331.10 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $315.10 | 2019-2024 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $261.34 | 2023-2024 | Rexulti, Nuedexta |
| Sanofi-Aventis U.S. LLC | $223.47 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $212.88 | 2019-2023 | Xarelto |
| Biohaven Pharmaceutical Holding Company LTD. | $203.91 | 2022 | |
| Astellas Pharma US INC | $163.07 | 2019-2025 | Veozah |
| Novartis Pharmaceuticals Corporation | $154.74 | 2019-2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $145.16 | 2023 | Hillrom - Carnation Ambulatory Monitor |
| Abbott Laboratories | $126.82 | 2021-2024 | Freestyle Libre 3 |
| E.R. Squibb & Sons, L.L.C. | $101.66 | 2019-2023 | Eliquis |
| Lundbeck LLC | $98.99 | 2022-2025 | Rexulti |
| Merck Sharp & Dohme LLC | $79.14 | 2019-2025 | Gardasil 9, Capvaxive |
| Takeda Pharmaceuticals U.S.A., INC. | $76.17 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $75.20 | 2020-2021 | |
| Dexcom, INC. | $60.21 | 2021-2024 | Dexcom G6 Transmitter |
| Collegium Pharmaceutical, INC. | $50.21 | 2023-2024 | Belbuca, Xtampza |
| Exact Sciences Corporation | $47.15 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Amarin Pharma, INC. | $38.08 | 2021 | |
| Circassia INC. | $35.06 | 2019 | |
| Viatris Specialty LLC | $29.06 | 2025 | Yupelri |
| Sanofi Pasteur INC. | $24.22 | 2023 | |
| Kowa Pharmaceuticals America, INC. | $23.35 | 2021 | |
| Axsome Therapeutics, INC. | $22.50 | 2025 | Auvelity |
| Mylan Specialty L.P. | $15.50 | 2021 | |
| Daiichi Sankyo INC. | $15.34 | 2021 | |
| Sumitomo Pharma America, INC. | $14.76 | 2024 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gilbert Desmangles listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.